Tiger Brokers

BRIEF-Vor Biopharma Says Primary Endpoint Achieved In Phase 3 Clinical Study Evaluating Telitacicept

Reuters
Nov 09
BRIEF-<a href="https://laohu8.com/S/VOR">Vor Biopharma</a> Says Primary Endpoint Achieved In Phase 3 Clinical Study Evaluating Telitacicept

Nov 8 (Reuters) - Vor Biopharma Inc VOR.O:

  • PRIMARY ENDPOINT ACHIEVED IN STAGE A OF A PHASE 3 CLINICAL STUDY EVALUATING TELITACICEPT IN ADULTS WITH IGA NEPHROPATHY

Source text: ID:nGNX6wP7Tm

Further company coverage: VOR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10